Clinical Trials Browser

Recruiting × Carcinoma, Non-Small-Cell Lung × Platinum Compounds × Clear all

Carcinoma, Non-Small-Cell Lung

NCT06465329 2026-02-12

A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Recruiting

120 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04585477 2026-02-10

Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)

Phase 2 Recruiting

80 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04486833 2026-01-21

Acclaim-1

Phase 1/2 Recruiting

158 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07320105 2026-01-06

Postoperative Radiotherapy for Postoperative N2 Metastases of NSCLC in the Immunotherapy Era (Phase II)

Phase 4 Recruiting

60 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06216301 2025-12-17

LUNAR-2

Phase 3 Recruiting

734 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT07170995 2025-11-18

Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer

Phase 3 Recruiting

460 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06623656 2025-10-23

Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC

Phase 2 Recruiting

112 enrolled

Thoracic

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT07084610 2025-08-22

Metabolic Biomarkers Predicting Response to Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer

Phase 2 Recruiting

30 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06313541 2024-06-05

Treatment Response Adapted Hybrid Radiotherapy in Metastatic Non-small Cell Lung Cancer Receiving First-line Immunotherapy

Phase 2 Recruiting

146 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06424899 2024-05-22

A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC

Phase 2 Recruiting

92 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

Clinical Trials

CEMI-LUNG

A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)

Acclaim-1

Postoperative Radiotherapy for Postoperative N2 Metastases of NSCLC in the Immunotherapy Era (Phase II)

LUNAR-2

Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer

Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC

Metabolic Biomarkers Predicting Response to Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer

Treatment Response Adapted Hybrid Radiotherapy in Metastatic Non-small Cell Lung Cancer Receiving First-line Immunotherapy

A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC